volume 2, issue 8, PS365-S366 2007
DOI: 10.1097/01.jto.0000283204.17566.c5
View full text
|
|
Share

Abstract: treat 1-and 2-overall survivals were 47% and 21%, respectively. Overall and median survivals between the two arms were not significantly different. In the patients who developed a rash ( 7), 1 complete and 4 partial responses were observed. This group of patients had a trend towards improved overall survival (log-rank 0.07). Conclusion:The addition of erlotinib to two standard chemoradiotherapy regimens is feasible and does not increase toxicities associated with chemoradiotherapy. C3-02Combined Modality Thera…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals